Molecular Mechanism of Naringenin Against High-Glucose-Induced Vascular Smooth Muscle Cells Proliferation and Migration Based on Network Pharmacology and Transcriptomic Analyses

Abstract

Although the protective effects of naringenin (Nar) on vascular smooth muscle cells (VSMCs) have been confirmed, whether it has anti-proliferation and anti-migration effects in high-glucose-induced VSMCs has remained unclear. This study aimed to clarify the potential targets and molecular mechanism of Nar when used to treat high-glucose-induced vasculopathy based on transcriptomics, network pharmacology, molecular docking, and in vivo and in vitro assays. We found that Nar has visible anti-proliferation and anti-migration effects both in vitro (high-glucose-induced VSMC proliferation and migration model) and in vivo (type 1 diabetes mouse model). Based on the results of network pharmacology and molecular docking, vascular endothelial growth factor A (VEGFA), the proto-oncogene tyrosine-protein kinase Src (Src) and the kinase insert domain receptor (KDR) are the core targets of Nar when used to treat diabetic angiopathies, according to the degree value and the docking score of the three core genes. Interestingly, not only the Biological Process (BP), Molecular Function (MF), and KEGG enrichment results from network pharmacology analysis but also transcriptomics showed that phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) is the most likely downstream pathway involved in the protective effects of Nar on VSMCs. Notably, according to the differentially expressed genes (DEGs) in the transcriptomic analysis, we found that cAMP-responsive element binding protein 5 (CREB5) is a downstream protein of the PI3K/Akt pathway that participates in VSMCs proliferation and migration. Furthermore, the results of molecular experiments in vitro were consistent with the bioinformatic analysis. Nar significantly inhibited the protein expression of the core targets (VEGFA, Src and KDR) and downregulated the PI3K/Akt/CREB5 pathway. Our results indicated that Nar exerted anti-proliferation and anti-migration effects on high-glucose-induced VSMCs through decreasing expression of the target protein VEGFA, and then downregulating the PI3K/Akt/CREB5 pathway, suggesting its potential for treating diabetic angiopathies.

Semaglutide ameliorates cardiac remodeling in male mice by optimizing energy substrate utilization through the Creb5/NR4a1 axis

“…5A ). Creb5 is a crucial component of the downstream signaling pathway of PI3K/AKT 32 . It is a member of the Creb (cAMP-responsive element-binding protein) family of proteins 33 .…”

CREB5 promotes the proliferation and self-renewal ability of glioma stem cells

“…As such, additional studies on these other genes and their association with CREB5 expression are important and could provide insights, especially on their role in GBM progression. Meanwhile, in recent studies it was reported that high glucose can activate the PI3K/Akt/CREB5 signaling pathway, resulting in excessive proliferation and migration of vascular smooth muscle cells [ 37 ]. Identifying the upstream regulatory elements that affect CREB5 expression and activity in GBM is also necessary.…”

SNHG 12 and hsa-miR-140-5P may play an important role in the ceRNA network related to hypertrophic cardiomyopathy

“…This effect involves β2-AR-dependent pathways involved in the control of CREB activity downstream of GSK3β ( 13 ). Furthermore, He et al ’s analysis showed that CREB5 is a downstream protein of the PI3K/Akt pathway that participates in vascular smooth muscle cells’ proliferation and migration which may lead to cardiomyocyte hypertrophy ( 14 ). In our study, we found that downregulation of hsa-miR-1244 and upregulation of hsa-miR-217 reduced upregulation of CREB5, and both effects were related to downregulation of SNH12.…”